港股异动 | CRO概念股集体走强药明康德(02359)上半年业绩预喜机构称CXO企业机遇充足

智通财经2025-07-11

智通财经APP获悉，CRO概念股集体走强，截至发稿，凯莱英(06821)涨13.59%，报89.45港元；药明康德(02359)涨9.15%，报87.1港元；昭衍新药(06127)涨8.81%，报27.5港元；康龙化成(03759)涨6.86%，报18.08港元；药明生物(02269)涨3.5%，报26.6港元。消息面上，药明康德发盈喜，预计2025年上半年实现营业收入约人民币207.99亿元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550605368?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-11 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550605368","market":"us","top_or_hot":-1,"title":"港股异动 | CRO概念股集体走强 药明康德(02359)上半年业绩预喜 机构称CXO企业机遇充足","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，CRO概念股集体走强，截至发稿，凯莱英(06821)涨13.59%，报89.45港元；药明康德(02359)涨9.15%，报87.1港元；昭衍新药(06127)涨8.81%，报27.5港元；康龙化成(03759)涨6.86%，报18.08港元；药明生物(02269)涨3.5%，报26.6港元。消息面上，药明康德发盈喜，预计2025年上半年实现营业收入约人民币207.99亿元，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1316564.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | CRO概念股集体走强 药明康德(02359)上半年业绩预喜 机构称CXO企业机遇充足</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | CRO概念股集体走强 药明康德(02359)上半年业绩预喜 机构称CXO企业机遇充足\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-11 09:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1316564.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，CRO概念股集体走强，截至发稿，凯莱英(06821)涨13.59%，报89.45港元；药明康德(02359)涨9.15%，报87.1港元；昭衍新药(06127)涨8.81%，报27.5港元；康龙化成(03759)涨6.86%，报18.08港元；药明生物(02269)涨3.5%，报26.6港元。消息面上，药明康德发盈喜，预计2025年上半年实现营业收入约人民币207.99亿元，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1316564.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516423091.SGD","symbol_name":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1316564.html","article_id":"2550605368","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550605368","pubTimestamp":1752198194,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，CRO概念股集体走强，截至发稿，凯莱英涨13.59%，报89.45港元；药明康德涨9.15%，报87.1港元；昭衍新药涨8.81%，报27.5港元；康龙化成涨6.86%，报18.08港元；药明生物涨3.5%，报26.6港元。消息面上，药明康德发盈喜，预计2025年上半年实现营业收入约人民币207.99亿元，同比增长约20.64%；预计归属于公司股东的净利润约人民币85.61亿元，同比增长约101.92%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","06127":"昭衍新药","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0051755006.USD":"摩根大通中国A (dist)","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","BK1191":"制药","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","CXO":"康休","02359":"药明康德","02269":"药明生物","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","06821":"凯莱英","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1997245177.USD":"安联神洲A股基金","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","BK1583":"高瓴概念","03759":"康龙化成","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK0216":"研究试验","BK1521":"挪威政府全球养老基金持仓","LU0052750758.USD":"富兰克林中国基金A Acc","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD"},"translate_title":"Changes in Hong Kong stocks | CRO concept stocks collectively strengthen WuXi AppTec (02359) 's first-half performance forecast is promising, institutions say there are sufficient opportunities for CXO companies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"CXO":1,"02269":0.9,"06127":0.9,"02359":1,"06821":0.9,"03759":0.9},"content_text":"智通财经APP获悉，CRO概念股集体走强，截至发稿，凯莱英(06821)涨13.59%，报89.45港元；药明康德(02359)涨9.15%，报87.1港元；昭衍新药(06127)涨8.81%，报27.5港元；康龙化成(03759)涨6.86%，报18.08港元；药明生物(02269)涨3.5%，报26.6港元。消息面上，药明康德发盈喜，预计2025年上半年实现营业收入约人民币207.99亿元，同比增长约20.64%；预计归属于公司股东的净利润约人民币85.61亿元，同比增长约101.92%。渤海证券近期指出，当下全球医疗健康产业融资企稳，医药市场研发支出持续增长，新药研发投资回报率出现下降，CXO企业机遇充足，行业持续扩容。SW医疗研发外包板块2024年有所承压，2025Q1企稳回升，拐点显现，头部企业2025Q1营收、业绩均提速，2024年大部分头部企业在手订单表现优异。中金认为，2025年，流动性预期乐观以及国内AI等技术突破等都导向以及创新药为代表的医药科技类资产更适合今年的投资环境。该行指出，受益于下游创新药板块今年的积极表现，一二级新药投融资环境改善，对以内需CRO和科研上游为代表的供应链体系有较为积极的订单改善边际影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550605368","isCrawlerRequest":true}

港股异动 | CRO概念股集体走强 药明康德(02359)上半年业绩预喜 机构称CXO企业机遇充足

精彩评论

港股异动 | CRO概念股集体走强药明康德(02359)上半年业绩预喜机构称CXO企业机遇充足